HRP20200918T1 - Modificirane mutirane fuzijske molekule interferonskog antitijela - Google Patents

Modificirane mutirane fuzijske molekule interferonskog antitijela Download PDF

Info

Publication number
HRP20200918T1
HRP20200918T1 HRP20200918TT HRP20200918T HRP20200918T1 HR P20200918 T1 HRP20200918 T1 HR P20200918T1 HR P20200918T T HRP20200918T T HR P20200918TT HR P20200918 T HRP20200918 T HR P20200918T HR P20200918 T1 HRP20200918 T1 HR P20200918T1
Authority
HR
Croatia
Prior art keywords
antibody
fusion molecule
molecule according
peptide linker
mutated
Prior art date
Application number
HRP20200918TT
Other languages
English (en)
Inventor
Iqbal Grewal
Sanjay D. Khare
Michael Gresser
Rashid Syed
Original Assignee
Immungene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immungene, Inc. filed Critical Immungene, Inc.
Publication of HRP20200918T1 publication Critical patent/HRP20200918T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Claims (8)

1. Genetski modificirana fuzijska molekula koja sadrži antitijelo (Ab) antigena povezanog sa tumorom (TAA) vezano za mutiranu molekulu interferona alfa (IFN-α), IFN-α mutiranu molekulu koja se sastoji od aminokiselinske sekvence navedene u SEQ ID NO: 13 pri čemu R149 je A i pri čemu R162 je A, i pri čemu je navedeno antitijelo vezano direktno za navedenu IFN-α mutiranu molekulu, pri čemu navedena fuzijska molekula kada je u kontaktu s tumorskom stanicom rezultira ubijanjem ili inhibicijom rasta ili proliferacijom navedene tumorske stanice.
2. Fuzijska molekula prema zahtjevu 1, naznačena time što je navedeno TAA antitijelo izabrano između anti-HER2/neu, anti-HER3, anti-HER4, anti-CD4, anti-CD 19, anti-CD20, anti-CD22, anti-CD25, anti-CD33, anti-CD138, anti-CD200, anti-CD276, anti-CXCR3, anti-CXCR5, anti-CCR3, anti-CCR4, anti-CCR9, anti-CRTH2, anti-PMCH i anti-endoplazminskog antitijela.
3. Fuzijska molekula prema bilo kojem od zahtjeva 1 ili 2, naznačena time što je navedeno TAA antitijelo izabrano od potpuno ljudskog antitijela, humaniziranog antitijela, himernog antitijela, monoklonskog antitijela, poliklonskog antitijela, rekombinantnog antitijela, fragmenta antitijela koje veže antigen, Fab, Fab', Fab2, Fab'2, IgG, IgM, IgA, IgE, scFv, dsFv i diatijela.
4. Fuzijska molekula prema bilo kojem od zahtjeva 1-3, naznačena time što je navedeno antitijelo vezano za navedenu mutiranu molekulu interferona s peptidnim veznikom.
5. Fuzijska molekula prema zahtjevu 4, naznačena time što navedeni peptidni veznik je peptidni veznik otporan na proteolizu.
6. Fuzijska molekula prema zahtjevu 5, naznačena time što je navedeni peptidni veznik izabran iz skupine koja se sastoji od SGGGGS i AEAAAKEAAAKAGS.
7. Farmaceutski pripravak koji sadrži fuzijsku molekulu prema bilo kojem od zahtjeva 1-6 u farmaceutski prihvatljivom nosaču.
8. Fuzijska molekula prema bilo kojem od zahtjeva 1-6 za uporabu u liječenju tumora ili metastaza tumora kod pacijenta.
HRP20200918TT 2012-03-03 2020-06-08 Modificirane mutirane fuzijske molekule interferonskog antitijela HRP20200918T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261634565P 2012-03-03 2012-03-03
EP13758471.0A EP2822575B1 (en) 2012-03-03 2013-03-04 Engineered antibody-interferon mutant fusion molecules
PCT/US2013/028899 WO2013134138A1 (en) 2012-03-03 2013-03-04 Engineered antibody-interferon mutant fusion molecules

Publications (1)

Publication Number Publication Date
HRP20200918T1 true HRP20200918T1 (hr) 2020-11-27

Family

ID=49042962

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200918TT HRP20200918T1 (hr) 2012-03-03 2020-06-08 Modificirane mutirane fuzijske molekule interferonskog antitijela

Country Status (15)

Country Link
US (3) US8980267B2 (hr)
EP (2) EP2822575B1 (hr)
JP (1) JP6195855B2 (hr)
CN (1) CN104470536A (hr)
AU (1) AU2013230484B2 (hr)
CA (1) CA2866126A1 (hr)
DK (1) DK2822575T3 (hr)
ES (1) ES2800426T3 (hr)
HR (1) HRP20200918T1 (hr)
HU (1) HUE049945T2 (hr)
IN (1) IN2014DN08236A (hr)
LT (1) LT2822575T (hr)
PL (1) PL2822575T3 (hr)
PT (1) PT2822575T (hr)
WO (1) WO2013134138A1 (hr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5591701B2 (ja) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
WO2014089354A1 (en) * 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN110526971B (zh) 2013-04-29 2023-06-30 泰华制药澳大利亚公司 抗-CD38抗体和与致弱干扰素α-2B的融合体
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
ES2757501T3 (es) 2013-07-18 2020-04-29 Vib Vzw Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾ｔｎｆファミリーメンバー
KR102275090B1 (ko) 2013-07-19 2021-07-09 브이아이비 브이지더블유 표적화된 변형된 il-1 패밀리 구성원
US9732135B2 (en) 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10544199B2 (en) * 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
WO2016201350A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Combination therapy for treatment of cancer
WO2016201337A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
AU2016274897B2 (en) * 2015-06-12 2021-02-25 Immungene, Inc. Focused interferon immunotherapy for treatment of cancer
US20190008983A1 (en) * 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071627B (zh) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 Cd8结合剂
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
WO2017173359A2 (en) * 2016-03-31 2017-10-05 University Of Southern California Methods of constructing immunoglobulin fusion proteins inhibiting cathepsin b and compositions thereof
WO2017180764A1 (en) * 2016-04-12 2017-10-19 Immungene, Inc. Focused interferon immunotherapy
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
CN106854248A (zh) * 2016-12-09 2017-06-16 中国药科大学 一种细胞因子突变体融合抗体的制备及其应用
EP3576765A4 (en) * 2017-02-06 2020-12-02 Orionis Biosciences, Inc. TARGETED ENGINEERING INTERFERON AND USES OF IT
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
WO2018146074A1 (en) * 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3642344A4 (en) * 2017-06-21 2021-03-31 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR CANCER CELL TARGETING CHIMERIC ANTIGEN RECEPTORS
CA3069017A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof
WO2019023156A1 (en) * 2017-07-24 2019-01-31 Rutgers, The State University Of New Jersey PHOSPHATIDYLSERIN-TARGETING FUSION MOLECULES AND METHODS OF USE
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN107556376B (zh) * 2017-09-08 2018-09-28 上海华新生物高技术有限公司 一种干扰素α-2b突变体及其制备方法和应用
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
CN109884313A (zh) * 2019-02-22 2019-06-14 武汉康圣达医学检验所有限公司 急性b淋巴细胞白血病微小残留的检测试剂盒
JP2022534837A (ja) 2019-03-28 2022-08-04 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
CN113840833A (zh) * 2019-03-28 2021-12-24 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
KR20210153092A (ko) 2019-04-15 2021-12-16 퀴셀 세라퓨틱스 엘엘씨 암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물
CN113151285B (zh) * 2019-12-30 2023-01-24 白素梅 人4IgB7-H3的突变编码基因及其调节免疫的应用
KR20240045278A (ko) * 2021-08-12 2024-04-05 상하이 티티엠-바이오 테크놀로지 컴퍼니 리미티드 이중특이적 재조합 단백질 및 이의 용도
CN114163522A (zh) * 2021-12-07 2022-03-11 重庆市动物疫病预防控制中心 一种可以高精确度和敏感性识别猪伪狂犬病毒的纳米抗体、制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1981A (en) 1841-02-18 backus
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4589071A (en) 1982-04-19 1986-05-13 Nissan Motor Co., Ltd. Method and apparatus for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CN1406249B (zh) * 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
BRPI0407533A (pt) 2003-02-18 2006-02-14 Merck Patent Ges Mit Beschaenk proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
RU2007105137A (ru) * 2004-07-13 2008-08-20 Байер Фармасьютикалс Корпорейшн (US) Улучшенные варианты апротинина
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
AU2006299901A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US7767799B2 (en) 2005-06-29 2010-08-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Nucleic acid molecules encoding recombinant interferon-α2 (IFNα2) mutants
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
JP5591701B2 (ja) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
EP2544519B1 (en) * 2010-03-12 2016-05-11 Forage Innovations B.V. Automatically steered gearboxes for an implement with a pivoting tongue
ES2695899T3 (es) 2010-06-16 2019-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Anticuerpos contra endoplasmina y su uso
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN110526971B (zh) 2013-04-29 2023-06-30 泰华制药澳大利亚公司 抗-CD38抗体和与致弱干扰素α-2B的融合体

Also Published As

Publication number Publication date
EP3799880A3 (en) 2021-06-23
ES2800426T3 (es) 2020-12-30
US10259854B2 (en) 2019-04-16
US9534057B2 (en) 2017-01-03
EP2822575A1 (en) 2015-01-14
JP6195855B2 (ja) 2017-09-13
DK2822575T3 (da) 2020-06-15
US20150139951A1 (en) 2015-05-21
JP2015515453A (ja) 2015-05-28
IN2014DN08236A (hr) 2015-05-15
CN104470536A (zh) 2015-03-25
US20130230517A1 (en) 2013-09-05
US20170073388A1 (en) 2017-03-16
AU2013230484B2 (en) 2017-04-27
LT2822575T (lt) 2020-06-25
US8980267B2 (en) 2015-03-17
PT2822575T (pt) 2020-07-02
HUE049945T2 (hu) 2020-11-30
EP2822575B1 (en) 2020-05-06
WO2013134138A1 (en) 2013-09-12
EP3799880A2 (en) 2021-04-07
AU2013230484A1 (en) 2015-02-12
CA2866126A1 (en) 2013-09-12
EP2822575A4 (en) 2016-07-06
PL2822575T3 (pl) 2020-08-10

Similar Documents

Publication Publication Date Title
HRP20200918T1 (hr) Modificirane mutirane fuzijske molekule interferonskog antitijela
US20210171661A1 (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP6793655B2 (ja) Ｃｄ２０結合分子およびその使用方法
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
IL259927B2 (en) Humanized antibodies against cd73
US20210188989A1 (en) Anti-4-1bb antibodies and methods of making and using thereof
JP2019524693A5 (hr)
JP2014527814A5 (hr)
JP2015524821A5 (hr)
JP2018510636A5 (hr)
RU2017105915A (ru) Антитела против pd-1
HRP20160009T1 (hr) Protutijela anti-cd37
JP2017149720A5 (hr)
AU2018248336A1 (en) Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
RU2016100892A (ru) Антитела против tweakr и их применение
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2015163068A5 (hr)
WO2018017761A1 (en) Multimeric cd137/4-1bb binding molecules and uses thereof
HRP20150641T1 (hr) Anti -cd38 humana antitijela i njihove uporabe
RU2016104130A (ru) Биспецифичные конструкции, связывающие антигены cd3 и cd19
HRP20240149T1 (hr) Bispecifična molekula za vezanje antigena, koji vežu cd3 i cd20, i njihove upotrebe
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2017507650A (ja) Ｐｄ−ｌ１に対するヒト抗体